info@seagull-health.com
SeagullHealth
search
Zongertinib(Hernexeos)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Hernexeos(Zongertinib) Instructions:Uses,Dosage, Side Effects
HERNEXEOS is a targeted therapy belonging to the kinase inhibitor class. Its active pharmaceutical ingredient is zongertinib. It is formulated as a 60 mg, yellow, film-coated tablet for oral administration, marked with "L6".
The medication is developed and distributed by Boehringer Ingelheim Pharmaceuticals, Inc., under license from Boehringer Ingelheim International GmbH.
HERNEXEOS is indicated for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy. This approval is under accelerated approval based on objective response rate and duration of response.
Administered orally once daily, with or without food. The dose is based on body weight: 120 mg for patients weighing less than 90 kg and 180 mg for patients weighing 90 kg or more. Treatment continues until disease progression or unacceptable toxicity.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
